EUVIMEDEUVIMED entdecken
Crossref

Utility of Relative Activity Factors to Determine Fraction Glucuronidation and Clearance of Icenticaftor in Humans

Mitesh Patel, Sahil Shaikh, Felix Huth, Sujal Deshmukh

Pharmaceutical Research · 2026

DOI: 10.1007/s11095-026-04136-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Research, 2026. Verfasst von Mitesh Patel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacokinetic Sciences, Novartis Biomedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA. mitesh.patel@novartis.com. Hauptthemen laut MEDLINE: Glucuronosyltransferase, Glucuronides, Liver. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The purpose of this study is to quantify the contribution of individual UDP-glucuronosyl transferase (UGT) enzymes involved in the glucuronidation of icenticaftor, which is primarily glucuronidated in the human liver to two distinct glucuronide metabolites that are ultimately excreted in the urine. METHODS: The formation of icenticaftor-glucuronide in recombinant UGT systems was scaled with relative activity factor (RAF) of involved UGT enzymes to determine the fraction glucuronidation in human liver. RESULTS: Scaling of the glucuronidation activity of UGT enzymes in recombinant UGT systems demonstrated that hepatic UGT1A9 contributed to about two-third of the overall icenticaftor glucuronidation while the remaining was accounted by UGT2B7. Moreover, the predicted UGT-mediated clearance of icenticaftor, upon scaling the intrinsic clearance (CLint) with RAF, correlates well with that estimated in humans. CONCLUSION: Collectively, current data are indicative of the utility of activity-based scalars to predict fraction glucuronidation and clearance of icenticaftor in the clinic. UGT1A9 is identified as the major UGT enzyme in the glucuronidation of icenticaftor in human liver.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucuronosyltransferaseGlucuronidesLiverHumansUDP-Glucuronosyltransferase 1A9Microsomes, LiverRecombinant ProteinsMetabolic Clearance RateAmidesPyridines

Stichwörter der Autor:innen

UDP-glucuronosyltransferasefraction glucuronidationhepaticicenticaftorrelative activity factor

Substanzen

GlucuronosyltransferaseGlucuronidesUDP-Glucuronosyltransferase 1A9UGT1A9 protein, humanUGT2B7 protein, humanRecombinant ProteinsicenticaftorAmidesPyridines

Autor:innen und Institutionen

  • Pharmacokinetic Sciences, Novartis Biomedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA. mitesh.patel@novartis.com.
  • Pharmacokinetic Sciences, Novartis Biomedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
  • Pharmacokinetic Sciences, Novartis BioMedical Research, Basel, Switzerland.

Zitieren

APA

Patel, M., Shaikh, S., Huth, F., & Deshmukh, S. (2026). Utility of Relative Activity Factors to Determine Fraction Glucuronidation and Clearance of Icenticaftor in Humans. Pharmaceutical Research. https://doi.org/10.1007/s11095-026-04136-x

Vancouver

Patel M, Shaikh S, Huth F, Deshmukh S. Utility of Relative Activity Factors to Determine Fraction Glucuronidation and Clearance of Icenticaftor in Humans. Pharmaceutical Research. 2026. doi:10.1007/s11095-026-04136-x

BibTeX
@article{Patel2026,
  author = {Patel, Mitesh and Shaikh, Sahil and Huth, Felix and Deshmukh, Sujal},
  title = {Utility of Relative Activity Factors to Determine Fraction Glucuronidation and Clearance of Icenticaftor in Humans},
  journal = {Pharmaceutical Research},
  year = {2026},
  doi = {10.1007/s11095-026-04136-x}
}
Kostenlos starten →